Table 1 Patients’ baseline characteristics.
All patients (%) | Premenopausal patients (%) | Postmenopausal patients (%) | P value | |
|---|---|---|---|---|
Total | 680 (100.0) | 379 (55.7) | 301 (44.3) | |
Age at diagnosis, median (range), years | 50.3 (25–81) | 43.5 (25–55) | 58.8 (43–81) | <.001 |
Tumor size, mm | .222 | |||
< 10 | 121 (17.8) | 76 (20.1) | 45 (15.0) | |
10–20 | 367 (54.0) | 198 (52.2) | 169 (56.1) | |
> 20 | 192 (28.2) | 105 (27.7) | 87 (28.9) | |
Pathologic nodal status | .736 | |||
None | 463 (68.1) | 265 (69.9) | 198 (65.8) | |
1 | 107 (15.7) | 55 (14.5) | 52 (17.3) | |
2–3 | 62 (9.1) | 35 (9.2) | 27 (9.0) | |
4–9 | 35 (5.1) | 18 (4.7) | 17 (5.6) | |
> 9 | 13 (1.9) | 6 (1.6) | 7 (2.3) | |
Histologic grade | .002 | |||
Low | 261 (38.4) | 161 (42.5) | 100 (33.2) | |
Intermediate | 342 (50.3) | 168 (44.3) | 174 (57.8) | |
High | 77 (11.3) | 50 (13.2) | 27 (9.0) | |
PR | < .001 | |||
Negative | 99 (14.6) | 30 (7.9) | 69 (22.9) | |
Positive | 581 (85.4) | 349 (92.1) | 232 (77.1) | |
HER2 | .572 | |||
Negative | 552 (81.2) | 313 (82.6) | 239 (79.4) | |
Positive | 79 (11.6) | 41 (10.8) | 38 (12.6) | |
Unknown | 49 (7.2) | 25 (6.6) | 24 (8.0) | |
Ki-67 LI | .250 | |||
≤ 20% | 562 (82.6) | 308 (81.3) | 254 (84.4) | |
> 20% | 97 (14.3) | 61 (16.1) | 36 (12.0) | |
Unknown | 21 (3.1) | 10 (2.6) | 11 (3.7) |
